Graves' disease in a patient with Down syndrome: a shift from hyperthyroidism to hypothyroidism

BMJ Case Rep. 2021 Sep 13;14(9):e242612. doi: 10.1136/bcr-2021-242612.

Abstract

Down syndrome (DS) is associated with an increased risk of multisystemic dysfunction, namely endocrine abnormalities. Thyroid dysfunction is the most common endocrinological disorder, and it can manifest as either hypothyroidism or hyperthyroidism. A 16-year-old patient with DS developed hyperthyroidism after a lifetime of alternating between subclinical hypothyroidism and euthyroidism. He presented new onset weight loss, agitation and diarrhoea. Laboratory studies were compatible with hyperthyroidism. Thyroid receptor antibodies (TRAbs) were positive, antithyroid peroxidase antibodies and thyroglobulin antibodies were negative. Antithyroid medication (methimazole) was prescribed and, despite therapy adjustments, laboratory evaluation revealed new onset hypothyroidism with persistently positive TRAbs. He experienced weight gain and remained in a hypothyroid state even with withdrawal of methimazole and administration of levothyroxine. This case illustrates an example of Graves' disease with coexisting stimulating and inhibiting TRAbs that led to a shift from hyperthyroidism to hypothyroidism, a rare condition in patients with DS.

Keywords: genetics; hyperthyroidism; thyroid disease.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antithyroid Agents / therapeutic use
  • Down Syndrome* / complications
  • Graves Disease* / complications
  • Graves Disease* / diagnosis
  • Graves Disease* / drug therapy
  • Humans
  • Hyperthyroidism* / complications
  • Hyperthyroidism* / drug therapy
  • Hypothyroidism* / complications
  • Hypothyroidism* / drug therapy
  • Male

Substances

  • Antithyroid Agents